BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210830
DTEND;VALUE=DATE:20210903
DTSTAMP:20260515T205451
CREATED:20210322T113138Z
LAST-MODIFIED:20210322T113138Z
UID:29478-1630281600-1630627199@www.pharmajournalist.com
SUMMARY:6th CAR-TCR Summit
DESCRIPTION:The CAR-TCR industry has started 2021 with a bang! With the 4th CAR-T gaining long-awaited approval\, Bristol-Myers Squibb have stepped onto the commercial stage\, and the CAR-TCR field continues to boom with excitement as the competition heats up. \nThe current approved therapies have encountered significant difficulties in the commercial market. Cell Therapies come with a high price tag\, little long-term efficacy data\, and expensive manufacturing processes. Now\, your community must gather to: \n\nAchieve consistency in manufacturing\, focusing on automation\, allogeneic platforms\, scalability\, and engineering techniques\nDemonstrate durable response with enhanced construct design\,optimized trial design\, and long-term follow-up data\nOvercome solid tumor hurdles with combination strategy\, specialized clinical delivery\, and next-generation engineering strategies\n\nThese challenges require ground-breaking work\, from discovery through to commercialization. Join the 6th CAR-TCR Summit to learn from the key opinion leaders\, and international innovators of the CAR-TCR community\, this September. \nSee more – https://ter.li/ofwzn3
URL:https://www.pharmajournalist.com/event/6th-car-tcr-summit/
LOCATION:Digital | EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210907
DTEND;VALUE=DATE:20210910
DTSTAMP:20260515T205451
CREATED:20210429T150915Z
LAST-MODIFIED:20210429T150915Z
UID:29950-1630972800-1631231999@www.pharmajournalist.com
SUMMARY:Next Generation Cancer Vaccine Development Summit 2021
DESCRIPTION:Cancer remains one of the most challenging diseases we face today. Standard treatment protocols (chemotherapy\, radiotherapy\, and surgical intervention) are often hampered by toxic side effects and concomitant malignancies. Vaccines offer a promising alternative to unleash the most powerful force against cancer: our own immune system! \n \nAt the inaugural Next Generation Cancer Vaccine Development Summit (September 7-9\, Digital Event) join the likes of Gritstone Oncology\, BioNTech\, Janssen\, (and much more!) as we come together to delve deep into understanding the tumor microenvironment\, optimising antigen selection\, and analyzing a multitude of novel platforms and combination therapies to finally bring safe and effective cancer vaccines to market. \nLearn more here: https://ter.li/m1zx7a
URL:https://www.pharmajournalist.com/event/next-generation-cancer-vaccine-development-summit-2021/
LOCATION:100% Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210907
DTEND;VALUE=DATE:20210910
DTSTAMP:20260515T205451
CREATED:20210517T084245Z
LAST-MODIFIED:20210517T084245Z
UID:30194-1630972800-1631231999@www.pharmajournalist.com
SUMMARY:2nd Operationalize: Decentralized Clinical Trials Summit
DESCRIPTION:By bringing together the world’s leading Decentralized Clinical Trials thinkers\, the 2nd Operationalize: Decentralized Clinical Trials Summit will clarify the complex issues through end-to-end remote\, decentralized\, and siteless clinical trial program operationalization. Through open discussion\, sharing best-practice case studies\, and removing the hypothetical: this meeting is your best chance to solve your challenges based on the wealth of experience collected in the last year of trial adaption. \n \nWhether it’s trial set-up\, technological integration\, negotiating with stakeholders\, hybridization\, patient communication\, and choice provision: ensure you aren’t repeating past mistakes by hearing global leaders recall their experience with a shared goal of providing you with pragmatic solutions to solve these complex hurdles. \nFeaturing real-life case studies and experiences as well as interactive panel discussions and virtual roundtables from the likes of PRA Health Sciences\, Boehringer Ingleheim\, Janssen\, Decentralized Trials & Research Alliance\, and the Digital Medicine Society\, this is your opportunity to find the answers to your most burning decentralized clinical trials challenges. \nJoin us to lead the industry by offering patients more flexibility through decentralized trials. \nTo know more about 2nd Operationalize: Decentralized Clinical Trials Summit please click here.
URL:https://www.pharmajournalist.com/event/2nd-operationalize-decentralized-clinical-trials-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210907
DTEND;VALUE=DATE:20210908
DTSTAMP:20260515T205451
CREATED:20210802T111449Z
LAST-MODIFIED:20210802T111449Z
UID:31182-1630972800-1631059199@www.pharmajournalist.com
SUMMARY:Multiscale and multi-modal insights into drug formulation
DESCRIPTION:SMi Group are delighted to introduce a free exclusive webinar taking place on 7th September 2021 at 3pm BST\, hosted by Zeiss. \nSynopsis / Webinar Overview: \nThe majority of pharmaceutical powders require a size <500 μm for ease of manufacture and biopharmaceutical performance. Powder behaviour of particles in this size-range spans cohesive to aeratable powders. Powder performance is dependent on the powder bulk density and micromeritic properties of individual particles\, but also crucially the structuring of particles within the powder bed. Micromeritic assessment is also routinely performed using image analysis or particle sizing techniques such as laser diffraction analysis. However\, there is a clear need for techniques that provide non-destructive granular information of pharmaceutical powder structures. \nFormulation equivalence between different batches of products or between comparator innovator and generic products has emerged as a hot topic of consideration in regulatory science. Microstructural equivalence (Q3) for powder products is complex\, and particularly in the case of Dry Powder Inhalation (DPI) formulations. It is in the characterization of the bulk powder that microstructural assessment is a particular challenge. Current methods for measuring critical material attributes such as the particle size and shape suffer from low resolution\, image in 2D or make shape assumptions. \nIn this webinar\, we will present some new approaches using X ray Microscopy (XRM) from nano- to micro-scale that can be utilized for characterizing inhalation powder blends non-destructively to obtain fully 3D information on particle size and shape\, its distributions\, and powder bed packing. Novel methodologies developed to identify individual chemical phases within blends\, their crystal orientations and interactions in 3D will also be presented. The results show the promise for XRM as a valuable powder characterisation technique that develops our fundamental understanding of powder microstructure\, and microstructural descriptors for the United States Food and Drug Administration Q3 microstructural assessments. \nRegister your free place: http://www.drug-formulation-zeiss-webinar.com/pjwl \nWho will be speaking? \nDr Hrishikesh Bale – Marketing Solutions Manager\, Engineering Materials\nCarl Zeiss – Research Microscopy Solutions \nKey Takeaways \nIn this webinar you will learn: \n\nAbout the importance of pharmaceutical powder microstructure and the current landscape of the methods for microstructural characterization\nHow X-ray Microscopy (XRM) can provide information on key microstructrual metrics\, as well as the interaction between formulation components\nHow the unique microstructural insight provided by XRM can help understand powder performance\nAbout a range of applications of XRM to pharmaceutical powders\, including powder beds and complex inhalation formulations\n\nRegister your free place: http://www.drug-formulation-zeiss-webinar.com/pjwl \nWho is this webinar aimed at? \nThis interactive webinar is designed for all users\, from both academic and industrial sectors\, who are interested in powder characterisation. The webinar is suitable for both a technical and non-technical audience and will provide insight into applications of XRM as a microstructural characterisation technique. \nAdditional Contact Info: \nT: +44 (0)20 7827 6088 \nE: hsidhu@smi-online.co.uk
URL:https://www.pharmajournalist.com/event/multiscale-and-multi-modal-insights-into-drug-formulation/
LOCATION:Webinar | 15pm BST
ORGANIZER;CN="SMi Events":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210913
DTEND;VALUE=DATE:20210915
DTSTAMP:20260515T205451
CREATED:20210420T085542Z
LAST-MODIFIED:20210420T085542Z
UID:29854-1631491200-1631663999@www.pharmajournalist.com
SUMMARY:Pre-filled Syringes San Francisco 2021
DESCRIPTION:As part of SMi’s leading Injectables series\, this year’s event will address the key drivers of the pre-filled syringes and combination products industry to give a comprehensive insight into the latest device innovations\, regulatory updates and future insights for the coming year. With the global market for prefilled syringes estimated to exceed $9.7bn by 2025\, the field is evolving at an exponential rate with connectivity and digital health strategies for devices and studies at the forefront. Furthermore\, this event will delve into the key takeaways following the global pandemic and discover how this will be used to enhance future drug delivery device development. \nThis comprehensive overview will explore the changing global market and latest innovations in device design and development for injectable drug delivery. Case studies from leading industry and regulatory experts will explore platform approaches for combination products\, enhanced device design and usability considerations\, change management and compatibility for novel drug products. \nThe two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nPlus\, two interactive post conference workshops:  \nA: Connected Devices and Digital Health: How to Navigate the U.S. FDA Usability Engineering Requirements \nWorkshop Leader: Shannon Clark\, CEO\, UserWise \nB: Postmarket Safety Reporting: The Current Regulatory Environment with a Global Impact \nWorkshop Leader: Khaudeja Bano\, Executive Medical Director\, Combination Product Safety Head\, Amgen \nBenefits of attending: \n\nEngage in case studies from big pharma leading experts on smart devices and connected delivery to aid the user experience\nExplore evolving device design and innovations for high volume and high viscous delivery\nDelve into regulatory updates on device development and human factors with insights from industry and regulatory bodies\nUncover how industry is incorporating risk management and controls into early stages for a holistic development process\n\nChairs for 2021: \n\nShannon Clark\, CEO\, UserWise\nPaul Upham\, Head Smart Devices\, Roche/Genentech\n\nFeatured 2021 speakers include: \n\nAlan M. Stevens\, Acting Director – Division of Drug Delivery\, General Hospital\, and Human Factors\, CDRH\, FDA\nGeorge Cusatis\, Director\, Regulatory Affairs\, Merck\nJames Robert Wise\, Associate Senior Consultant Engineer\, Eli Lilly\nJim Leamon\, Director of Biologics Device Development\, Jazz Pharmaceuticals\nScott Surrette\, Manager Combination Product Development\, Regeneron\nJace Blackburn\, Smart Device Engineer\, Roche/Genentech\nAlasdair Young\, Senior Director\, Device Engineering\, Coherus BioSciences\nRachel Poker\, Human Factors Engineering Manager\, Device Development\, AstraZeneca\nYoung Chun\, Associate Director – Lead Human Factors and User Research\, R&D/Medical Devices Center of Excellence\, Takeda\nMehak Mehta\, Scientist II\, Protein Drug Product Development\, Biogen\nAlie Jahangir\, Sr. Principle Engineer\, Combination Products and Emerging Technologies\, Janssen Pharmaceuticals\nSindhuja Kuchibhatla\, Device Development Engineer\, New Technologies Management\, Regeneron Pharmaceuticals\n\n\nEARLY-BIRD RATES: \n\nBOOK BY 28TH MAY AND SAVE £200\nBOOK BY 30TH JUNE AND SAVE £100\n\nAdditional Contact Info:\nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk \nLinkedIn: @SMi Pharma\nTwitter: #smipfsusa
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-san-francisco-2021/
LOCATION:Hyatt Centric Fisherman’s Wharf\, San Francisco (Virtual Attendance Option Available)
ORGANIZER;CN="SMi Group":MAILTO:EVENTS@SMI-ONLINE.CO.UK
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210914
DTEND;VALUE=DATE:20210917
DTSTAMP:20260515T205451
CREATED:20210609T105252Z
LAST-MODIFIED:20210609T105252Z
UID:30495-1631577600-1631836799@www.pharmajournalist.com
SUMMARY:Gene Therapy for Metabolic Disorders
DESCRIPTION:More companies and institutions than ever before are embarking on development of gene therapies in metabolic disease\, and they are encountering unique challenges\, from fine-tuning dosing to defining clinically relevant biomarkers. Gene Therapy for Metabolic Disorders will unite large pharma and innovative biotechs to collectively overcome translational drug development barriers to deliver on the transformative promise of gene therapy approaches for patients in need.  \nIncorporating in-depth insights into the leading metabolic disease programs\, this event will ensure that you can optimize dosing to achieve the required enzyme levels without over-expression\, define the necessary parameters for transitioning to first-in-human trials\, and overcome unique challenges encountered in multi-organ systemic gene therapy delivery for complex metabolic indications.  \nDon’t get left behind. Join colleagues from Preclinical\, Translational and Clinical departments of leading companies including AVROBIO\, Freeline Therapeutics and LogicBio to optimize your gene therapy approach and revolutionize the treatment of metabolic diseases. \nTo know more about Gene Therapy for Metabolic Disorders please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-for-metabolic-disorders/
LOCATION:Digital Event | EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210916
DTEND;VALUE=DATE:20210919
DTSTAMP:20260515T205451
CREATED:20210709T101326Z
LAST-MODIFIED:20210709T101326Z
UID:30866-1631750400-1632009599@www.pharmajournalist.com
SUMMARY:CRISPR 2.0 Summit
DESCRIPTION:In the time since its discovery\, CRISPR has rapidly become an established tool in the genomics toolbox. Now the question is: What next? \nThe CRISPR 2.0 Summit is devoted to showcasing only the latest and greatest innovations by uncovering how the next generation of CRISPR tools are radically enhancing efficacy\, minimizing off-target effects & enabling efficient delivery to specific tissues to ensure you stay at the forefront of this rapidly exploding field. \n \nDiscover the promise of novel Cas variants\, base and prime editing approaches\, innovative delivery mechanisms\, and the applications of these next generation tools through learnings from CRISPR clinical trials and new & unpublished data. \nDon’t get left behind. Join 100+ leading pharma and biotech companies pioneering CRISPR-based therapeutics into the clinic to usher in the next generation of safe\, targeted and effective genome editing. \nRather than attending yet another CRISPR meeting that covers old ground\, CRISPR 2.0 will offer you the opportunity to: \n\nDiscuss methods to overcome CRISPR delivery challenges and delve into the latest delivery platforms with innovative work on the developments of viral and non-viral candidates suitable for ex-vivo and in-vivo delivery with Scribe Therapeutics and AskBio\nExplore the potential of novel prime and base editing\, improving on editing accuracy. Hear directly from Andrew Anzalone\, the pioneer that developed prime editing and Astrazeneca on how to improve safety\nAccelerate the development of therapeutics utilizing CRISPR and discover the clinical applications that are being studied with insights and data from Intellia Therapeutics\, and Graphite Bio\nInvestigate novel Cas variants and understand how novel Cas proteins that optimize specificity and efficacy of gene editing will be vital to bringing CRISPR successfully into the clinic with Arbor Biotech and Harvard Medical School\n\nTo know more about CRISPR 2.0 Summit please click here.
URL:https://www.pharmajournalist.com/event/crispr-2-0-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210920
DTEND;VALUE=DATE:20210922
DTSTAMP:20260515T205451
CREATED:20210423T132650Z
LAST-MODIFIED:20210423T132650Z
UID:29926-1632096000-1632268799@www.pharmajournalist.com
SUMMARY:SMi’s Aseptic Processing Conference
DESCRIPTION:Sponsored by: Innerspace\, Solo Containment and STERIS\nCo-Chairs: Richard Denk\, Senior Consultant Aseptic Processing and Containment\, SKAN AG \nJames Drinkwater\, Head of Aseptic Processing and Containment Special Interest Group\, PHSS and Head of GMP Compliance\, F Ziel GmbH \nExploring Effective Strategies and New Regulations for Compliant Pharmaceutical Manufacturing \nThe aseptic processing industry has seen many changes during its progression towards the 21st century. With advances in innovative therapeutic manufacturing such as ATMPs\, pragmatic barrier system applications\, adaptability and modularity in fill finish\, robotics and automation\, small and agile product manufacturing\, just to name a few. In 2018\, the global aseptic processing market was valued over $56 trillion and is estimated to increase in net revenue upwards $124 trillion by 2027\, with a CAGR growth of 9.18%. \nThe industry is ever changing and with the advent of innovative therapeutics taking hold\, regulators and industry leaders are prompted to take proactive approaches to get treatments to patients faster. \nJoin us to explore novel and developing technologies that tackle the most pressing challenges and push innovation in the world of aseptic processing and sterile manufacturing. \nEvent Hashtag: #SMiAseptic \nKey Highlights Include: \n\nDiscuss the revisions and the impact of Annex 1 on aseptic manufacturing with AstraZeneca\nListen to a field report on the implementation of a global contamination control program with Takeda\nExplore the applications of rapid micro methods in the manufacture of sterile products with AbbVie\nDiscover a Risk Based Approach to Cleaning and Disinfection with STERIS\nDelve into case studies of competence in global aseptic manufacturing with Fresenius Kabi\nUncover the journey of Isolation Technology in a large Biotech pharmaceutical plant with Eli Lilly\n\n Who Should Attend? \n\nValidation Managers\nSenior Microbiologists\nSenior QA’s and QC’s\nQuality Control Managers\nHeads of GMP Compliance\nQuality Assurance Experts\nTechnical Operations Leads\nLeaders in Sterility Assurance\nCleanroom Managers\nRegulatory Affairs Managers\nProduction Managers\nQuality Systems Managers\nHeads of Quality Compliance\nProcess Leaders\nSenior Auditors\nBioprocess Research & Development\n\nPLUS – Post-Conference Workshop on… \nContamination Control Measures in Good Manufacturing Practice (GMP) Applied to Aseptic Processing\nWorkshop Leaders: James Drinkwater\, Head of Aseptic Processing and Containment Special Interest Group\, PHSS and Head of GMP Compliance\, F Ziel GmbH Kevin Jenkins\, Consultant\, Quality Excellence Consulting
URL:https://www.pharmajournalist.com/event/smis-aseptic-processing-conference/
LOCATION:Copthorne Tara Hotel\, London\, UK – (Virtual Attendance Option Available)
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210921
DTEND;VALUE=DATE:20210924
DTSTAMP:20260515T205451
CREATED:20210524T075240Z
LAST-MODIFIED:20210625T075240Z
UID:30287-1632182400-1632441599@www.pharmajournalist.com
SUMMARY:3rd Annual RAS–Targeted Drug Development Summit
DESCRIPTION:As 2021 marks a major milestone for RAS therapeutics\, with the first ever KRAS targeted therapy receiving FDA approval\, the once undruggable RAS family of proteins is no longer impossible to crack. With this significant industry shift\, this community will no doubt continue going from strength to strength and the future looks bright for future development of RAS targeted therapies that safely\, effectively\, and selectively drug all RAS driven cancers beyond those caused by G12C mutation. \n \nThe 3rd Annual RAS Targeted Drug Development Summit is returning once again this September to reunite the biggest community of thought leaders and experts in Oncology\, Cancer Therapeutics and Clinical Development to discuss robust monotherapies or combination strategies capable of specifically targeting different RAS-mutant cancer cells with less toxicity to enhance the impact of RAS therapies against all RAS driven cancers beyond lung. \nVia the latest preclinical\, translational and clinical development data-driven case studies from academic and industry pioneers\, the 3rd RAS Targeted Drug Development Summit is your only comprehensive roadmap to addressing unique challenges and future directions of finally drugging all RAS mutations and associated targets with novel modalities and next generation combination therapies. \nIncorporating tracks taking a deep dive into accelerating emerging modalities\, validating robust combination strategies and advancing clinical development\, this is your opportunity to gain extensive strategic and scientific information enabling you to solve the exact challenges you’re encountering to support development of safe and effective next generation RAS targeted therapies. \nTo know more about 3rd Annual RAS–Targeted Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-annual-ras-targeted-drug-development-summit/
LOCATION:Digital Event\, EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210921
DTEND;VALUE=DATE:20210924
DTSTAMP:20260515T205451
CREATED:20210524T114355Z
LAST-MODIFIED:20210524T114355Z
UID:30320-1632182400-1632441599@www.pharmajournalist.com
SUMMARY:4th International Cannabinoid Derived Pharmaceuticals Summit
DESCRIPTION:The Cannabinoid Derived Pharmaceuticals Summit is the world’s largest conference devoted exclusively to the production of CDPs for medical conditions using FDA/EMA approval pathways. The 2021 agenda will focus on clinical trial design and commercialization\, target biology and pharmacology\, GMP-compliant product formulation\, drug delivery\, and managing the changing regulatory environment (particularly in light of new policies from the US government administration). \n \nThe Three-day Program Spans: \n\nA brand-new section dedicated to building a robust clinical strategy will equip you with the knowledge that gave world leading cannabinoid drug developers a commercial and clinical edge in the race to approval\nAnalyzing new discoveries in cannabinoid pharmacology and ECS biology to identify new opportunities\nDiscussion of vital IP and investment topics for a comprehensive update on the health of the industry\nPreparation for post-approval through exploration of key issues relating to commercialization and supply chain management of cannabinoid medicine products and APIs\n\nThe 4th International Cannabinoid-Derived Pharmaceuticals Summit brings together drug developers working on the complex and difficult production of both plant-based and synthetic endocannabinoid system modulators. An elite panel of speakers will discuss important topics such as rigorous clinical trial data exchange\, guided discussion\, and industry networking. \nMeet face-to-face with decision makers from the likes of Greenwich Biosciences\, ACHEM\, Cannvalate\, Cannabics Pharmaceuticals\, Oxford Cannabinoid Technologies and more at the first physical cannabinoid conference of the year. \nTo know more about 4th International Cannabinoid Derived Pharmaceuticals Summit please click here.
URL:https://www.pharmajournalist.com/event/4th-international-cannabinoid-derived-pharmaceuticals-summit/
LOCATION:Aloft Boston Seaport District\, 401-403 D St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210921
DTEND;VALUE=DATE:20210924
DTSTAMP:20260515T205451
CREATED:20210525T115351Z
LAST-MODIFIED:20210525T115440Z
UID:30335-1632182400-1632441599@www.pharmajournalist.com
SUMMARY:2nd Gene Therapy for Ophthalmic Disorders
DESCRIPTION:Returning in September as a digital event\, the 2nd Gene Therapy for Ophthalmic Disorders meeting will target the industry’s translational challenges in targeting both rare and common ophthalmic disorders including wet AMD\, dry AMD\, DME\, IRDs and more. \nDiscover novel vectors and administration routes for optimal retinal delivery with 30+ world class speakers from the likes of GenSight Biologics\, Biogen\, Gyroscope Therapeutics\, Novartis\, Horama and REGENXBIO \n \nJoin 150+ fellow industry attendees from discovery\, preclinical and clinical backgrounds\, to learn lessons in rare disorders and seize the opportunity in common ophthalmic disorders. \nThis meeting will allow you to: \n\nHear the latest data in ocular gene therapy immunogenicity and vector strategies to overcome Inflammation\nHighlight optogenetics and gene agnostic approaches from SparingVision\, GenSight Biologics and Bionic Sight\nLearn how Clearside Biomedical are progressing suprachoroidal delivery with the potential to minimize invasive surgical procedures\nDiscuss the clinical progress with different administration routes to the eye with clinical experience from REGENXBIO\nGain key vector insights from Eyevensys\, who are developing non-viral vectors to minimize immune response and increase likelihood or re-dosing\nExplore the realities of clinical trial design to meet regulatory expectations throughout a program\, with insights from Gensight Biologics\nHear pharma representatives discuss the opportunities and realities of collaborating with biotechs\, with experience from Novartis\nHear from a Luxturna patient to understand their first-hand experience of receiving the therapy\, and have an opportunity to ask them your questions\nHighlighting progress in ASOs for ophthalmic disorders for a deeper understanding of the ophthalmic landscape with data from ProQR\n\nView the event guide here for full agenda details and the expert speaker faculty.
URL:https://www.pharmajournalist.com/event/2nd-gene-therapy-for-ophthalmic-disorders/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210921
DTEND;VALUE=DATE:20210924
DTSTAMP:20260515T205451
CREATED:20210610T122026Z
LAST-MODIFIED:20210610T122340Z
UID:30508-1632182400-1632441599@www.pharmajournalist.com
SUMMARY:6th Annual PREDiCT: 3D Tissue Models Summit
DESCRIPTION:The 6th PREDiCT: 3D Tissue Models Summit is the only industry-led summit focusing on real-world application of 3D models in drug discovery and development. With 25+ experts sharing fresh case studies on 3D Tissue Models data\, how to foster technology maturation\, and lower costs to drive industrial adoption\, this is a conversation not to miss. \n \nReturning as an in-person meeting in Boston\, our 2021 program will delve further into advanced 3D organoids\, organ-on-chips\, microphysiological systems (MPS)\, and tissue engineering – from oncology to other therapeutic areas – not only in preclinical safety and toxicology models but also back to translation in clinical Ph1 for biomarkers and patient stratification for better Ph2 design. \nJoin 80+ experts on scientific and real-world application dialogues with the likes of FDA\, GSK\, Takeda\, MIT\, and many more\, sharing their journeys and lessons learned with complex in vitro models\, compared with conventional in vivo and 2D cell studies. \nTo find out more and view the 2021 speaker line-up\, download the full event guide. \nBook with confidence! – As the world begins to re-open and in-person events become a reality\, join us again in Boston for the first time in more than a year\, to learn expert insights and generate quality industry connections in a face-to-face capacity. See how we’ll ensure your safety here.
URL:https://www.pharmajournalist.com/event/6th-annual-predict-3d-tissue-models-summit/
LOCATION:The Colonnade Boston – 120 Huntington Avenue\, Boston\, MA 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210922
DTEND;VALUE=DATE:20210924
DTSTAMP:20260515T205451
CREATED:20200416T105628Z
LAST-MODIFIED:20200710T092049Z
UID:25059-1632268800-1632441599@www.pharmajournalist.com
SUMMARY:Oligonucleotide Therapeutics and Delivery Conference
DESCRIPTION:On the way to maximising the potential of oligo-based medicine \nOligonucleotide therapeutics – the emerging medicine class – are harnessing the therapeutic benefit of targeting genetic material via antisense\, mRNA\, RNAi\, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules. They bring about the ability to affect targets that have been considered “non-draggable”. Heavy investments in oligonucleotide therapeutic discovery have created an emerging market need for drug delivery technologies. \n \nSMi’s inaugural Oligonucleotide Therapeutics and Delivery conference is here to keep you updated. By bringing together leading representatives of pharmaceutical\, biotechnology and academic institutions\, the 2-day conference will provide first-hand information on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. From optimizing particle size to choosing the right nanocarrier systems\, the conference will address delivery to non-hepatocyte cells such as cancerous tissues and overview the most successful platforms. Discussions will be centered around improving targeted therapy uniting the field’s biggest players to share their opinions. \nEstablished on the success of our RNA Therapeutics series\, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments. \nBenefits of attending: \n\nGain first-hand insight into oligonucleotide therapy clinical success up to date for improving development of novel agents in your pipeline\nListen to case studies presenting the latest candidates undergoing pre-clinical and clinical research\nDeepen your understanding of crucial delivery methods and available platforms for non-hepatocytic delivery\nCollaborate with members of the oligonucleotide community leading pharmaceutical\, biotechnology and academic representatives to maximise future opportunities\n\nPlus\, an interactive half day pre-conference workshop on Oligonucleotide drug discovery: Target selection\, delivery\, molecular design and lead identification. \nCHAIR FOR 2021:  \n\nNagy Habib\, Head of HBP Surgery\, Imperial College London and Co-Founder\, Head CNN of R&D and Chief Medical Officer\, Mina Therapeutics\n\nSCIENTIFIC ADVISORY BOARD 2021:\n \n\nEkkehard Leberer\, Senior Director\, Alliance Management\, Sanofi\nMark Edbrooke\, Independent Consultant\nTroels Koch\, Chief Technology Officer\, SVP Science and Technology\, Inexos Therapeutics\nSudhir Agrawal\, Founder and President\, ARNAY Sciences and Idera Pharma and Professor\, University of Massachusetts Medical School\n\nFEATURED 2021 SPEAKERS INCLUDE:  \n\nDavid Evans\, Chief Scientific Officer\, Sirnaomics\nAlexey Wolfson\, CEO\, Advirna\nStefan Vonhoff\, VP Chemistry & Manufacturing\, NOXXON Pharma\nVera Brinks\, Director Pharmaceutics\, ProQR Therapeutics\nMatthew Catley\, Research Director\, MiNa Therapeutics\nSteve Pascolo\, Founder and CEO\, Miescher Pharma\n\nWho should attend: \n\nRNA Biology/Discovery\nNovel Therapeutic Modalities\nInnovation Technologies\nC-level Scientific Executives\nFormulation and Drug Delivery\nClinical Research and Development\nCell Biology\n\nAdditional Contact Info:\nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk \nLinkedIn: @SMi Pharma\nTwitter: #SMiOligonucleotides
URL:https://www.pharmajournalist.com/event/oligonucleotide-therapeutics-and-delivery-conference/
LOCATION:Holiday Inn Kensington Forum\, London\, London\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210922
DTEND;VALUE=DATE:20210924
DTSTAMP:20260515T205451
CREATED:20200427T082728Z
LAST-MODIFIED:20200605T145115Z
UID:25298-1632268800-1632441599@www.pharmajournalist.com
SUMMARY:Aseptic Processing Conference
DESCRIPTION:SMi’s Aseptic Processing Conference\nExploring aseptic facility design and operation to implement agile contamination control strategies Conference: 22 – 23 September 2021\nLocation: Copthorne Tara Hotel\, London\, UK\nWebsite: http://www.asepticprocessing.co.uk/PJWL \nSPONSORED BY: Innerspace & Steris  \nCHAIRED BY: James Drinkwater\, Head of Aseptic Processing & Containment Special Interest Group\, PHSS and Richard Denk\, DACH Affiliate\, ISPE  \n \nThe aseptic processing industry has seen many changes during its progression towards the 21st century. With advances in innovative therapeutic manufacturing such as ATMPs\, pragmatic barrier system applications\, adaptability and modularity in fill finish\, robotics and automation\, small and agile product manufacturing\, just to name a few. In 2018\, the global aseptic processing market was valued over $56 trillion and is estimated to increase in net revenue upwards $124 trillion by 2027\, with a CAGR growth of 9.18%. \nThe industry is ever changing and with the advent of innovative therapeutics taking hold\, regulators and industry leaders are prompted to take proactive approaches to get treatments to patients faster. \nJoin us to explore novel and developing technologies that tackle the most pressing challenges and push innovation in the world of aseptic processing and sterile manufacturing.  \nEvent Hashtag: #SMiAseptic \nAt the Aseptic Processing Conference\, you will gain insight into: \nFeatured 2021 Speakers include: \n\nScott Nichols\, Microbiologist\, FDA\nSerena Ambrosini\, Sterile Manufacturing Manager\, AstraZeneca\nJim Polarine\, Senior Technical Service Manager\, Steris Corporation\nDi Morris\, Audit Manager CAG\, GSK\nStephen Yang\, Director\, Global Sterile Validation COE\, Merck\nKevin Jenkins\, Consultant\, Quality Excellence Consulting\n\n KEY HIGHLIGHTS INCLUDE FOR 2021 \n\nDiscuss the latest regulatory updates in the industry from leading regulatory bodies\nListen to global case studies in aseptic competence from companies pioneering in the pharmaceutical industry\nExplore advances in ATMP facility design that are revolutionising aseptic manufacturing\nDelve into the newest contamination control technologies from VHP disinfection to fully automated pipelines \n\nPLUS – Pre-conference workshop on… \nContamination control measures in Good Manufacturing Practice (GMP) applied to Aseptic processing \nWorkshop leaders:  James Drinkwater\, Head of Aseptic Processing and Containment Special Interest Group\, PHSS and Kevin Jenkins\, Consultant\, Quality Excellence Consulting \nView the brochure and to download visit http://www.asepticprocessing.co.uk/PJWL
URL:https://www.pharmajournalist.com/event/aseptic-processing-conference/
LOCATION:COPTHORNE TARA HOTEL\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210928
DTEND;VALUE=DATE:20211001
DTSTAMP:20260515T205451
CREATED:20210524T114659Z
LAST-MODIFIED:20210524T114953Z
UID:30324-1632787200-1633046399@www.pharmajournalist.com
SUMMARY:4th Annual Neuropsychiatric Drug Development Summit
DESCRIPTION:This last year has been a brutal reminder as to how crucial it is that we tackle the impending global mental health crisis and find a path towards successful neuropsychiatric drug development. \nWe are proud to be the industry’s definitive and unrivalled forum focused on encapsulating the recent clinical advances across this extremely arduous field. This timely meeting provides a much-needed platform for industry and academic thought leaders to: \n\nInvestigate new treatment paradigms to support schizophrenia patients with Sunovion\, Merck\, Cerevel and BioXcel\nStrive for useful biomarkers in clinical practice and explore novel electrophysiological biomarkers of synaptic plasticity in humans with Lundbeck\, Daniel Javitt and Takeda\nHear patient-centric approaches towards developing efficacious and engaging digital therapeutics with Thomas Insel\, MindMed\nDecipher the recent hype in psychedelics by evaluating new data emerging on hallucinogens with Psilera\, MAPS\, Eleusis\, ATAI and Perception Neuroscience\nDiscover the major advances in understanding neuroinflammation across CNS indications and how can we use this to help us further understand psychiatric conditions with Johnson & Johnson and Inmune Bio\n\nDon’t miss out and join over 80 of your peers at this timely event to take a step closer towards your ambitious goal of drastically improving the lives of individuals living with neuropsychiatric disorders. \nTo know more about 4th Annual Neuropsychiatric Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/4th-annual-neuropsychiatric-drug-development-summit/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210929
DTEND;VALUE=DATE:20211002
DTSTAMP:20260515T205451
CREATED:20210521T123937Z
LAST-MODIFIED:20210521T124307Z
UID:30236-1632873600-1633132799@www.pharmajournalist.com
SUMMARY:12th Annual World Bispecific Summit
DESCRIPTION:The 12th Annual World Bispecific Summit will deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover unique discovery\, translational\, and manufacturing challenges faced in the bispecific field. Whatever your role and interest\, you will leave the meeting with concrete methods to employ into your strategy and pipeline to convert the promise of bispecific therapeutics into a reality for patients. \n \nDiscover who the 45+ expert speakers are\, and the topics they will examine\, including how: \n\nOSE Immunotherapeutics is pioneering their unique platform BiCKI a bispecific platform optimized for the development and manufacturing of bispecific cytokine fusion proteins\nGT Biopharma and Light Chain Bioscience are showcasing the next generation of innate cell engagers for the treatment of solid tumors\nMerus\, Pfizer\, and Innate Pharma are expanding the boundaries of biotherapeutics with tri-specific and multi-specific antibodies\nGenentech\, Pfizer\, and City of Hope are discussing approaches to reduce on-target off-tumor toxicities including dosing strategies in liquid and solid tumor indications\nXencor\, Harbour Biomed\, and Harpoon Therapeutics will discuss their unique platforms and CMC strategies for scale-up and production\nIGM Biosciences and MacroGenics will evaluate biomarker strategies for bispecific candidates during clinical development\n\nTo know more about 12th Annual World Bispecific Summit please click here.
URL:https://www.pharmajournalist.com/event/12th-annual-world-bispecific-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210929
DTEND;VALUE=DATE:20211001
DTSTAMP:20260515T205451
CREATED:20210721T205309Z
LAST-MODIFIED:20210721T205309Z
UID:31026-1632873600-1633046399@www.pharmajournalist.com
SUMMARY:11th World Clinical Biomarkers & CDx Summit
DESCRIPTION:Accelerating R&D to Commercialization by Leveraging Predictive Biomarkers & Clinical Diagnostics Evidence for Best Patient Outcomes in Target Populations \nThe 11th World Clinical Biomarkers & CDx Summit returns in 2021 as the only end-to-end industry-led meeting diving deep into the science of transitioning biomarkers to the clinic\, their clinical validation and later commercialization with a CDx. \nWith over half of drugs approved by the FDA now supported by a biomarker and as new CDx collaborations are announced on an almost weekly basis\, demand for diagnostic tools enabling earlier\, more precise\, therapeutic interventions is at an all time high. Join with 650+ key stakeholders across biomarker\, translational\, clinical\, regulatory and commercial functions to tackle end-to-end challenges and deliver game-changing drug-Dx products to market. \nAcross 2 days of comprehensive content\, 65+ global expert speakers will share fresh data paired with inspiring stories from innovative partnership collaborations to help you overcome your most pressing challenges and accelerate curative medicine for heterogeneous patient populations. \nWith 3-tracks addressing the entire lifecycle of biomarker-driven drug development\, explore biomarkers and Dx movement within bioanalytical analysis\, AI/ML application\, data sharing and the regulatory and payer landscape. Covering immune-oncology\, neurodegenerative\, metabolic\, autoimmune and rare indications\, gain a diverse picture of today’s expanding personalized medicine ecosystem. \nThis is your unmissable event\, bringing you the tools\, insights and techniques to design a clinically robust biomarker and commercially competitive CDx! \nTo know more visit: https://world-cdx.com/
URL:https://www.pharmajournalist.com/event/11th-world-clinical-biomarkers-cdx-summit/
LOCATION:Digital
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR